DeLorean AI's Cardio AI Cuts Heart Failure Costs by $350K Per Patient

DeLorean AI, a healthtech company based in Palm Beach, has released a new white paper demonstrating the capabilities of its Cardio AI platform. The paper shows that the platform can identify patients at risk of progressing to heart failure before symptoms appear, enabling earlier intervention. This predictive AI technology has shown 87% sensitivity in predicting heart failure progression using data from 12 million patient records according to the white paper.

Heart failure is a costly and deadly condition in the U.S., with over $350,000 in annual costs per patient. DeLorean AI claims its models can cut these costs by as much as $250,000–$350,000 annually by identifying risk early and implementing proactive care. The platform integrates with electronic health records and provides clinicians with actionable insights and next-best actions to prevent adverse events.

Dr. Severence MacLaughlin, CEO and founder of DeLorean AI, emphasized the importance of predictive AI in value-based care. He stated that having predictive visibility into patient deterioration could stabilize current payment structures and allow providers to deliver more effective care. Cardiovascular disease remains a top driver of U.S. healthcare expenditures, and heart failure contributes significantly to the $417.9 billion in annual costs.

How the Technology Works

DeLorean AI's Cardio AI platform analyzes longitudinal data from electronic health records (EHR) and claims to provide predictive insights about patient deterioration. The platform identifies early signs of deterioration from conditions like hypertension or ischemic heart disease toward heart failure. It can predict whether a patient's condition will improve, worsen, or remain stable with 85–87% accuracy. Additionally, the system can forecast acute heart failure hospitalization up to 90 days in advance, enabling timely intervention.

The models are trained on a dataset of over 80 million patient records and have outperformed peer-reviewed studies in terms of accuracy and scalability. By leveraging AI, DeLorean AI aims to offer precision in care delivery, reducing preventable hospitalizations and healthcare spending. The platform surfaces patient-specific next-best actions based on evidence-based medicine, helping clinicians make informed decisions.

Market Potential and Impact

With over three million Americans at elevated risk for heart failure, the potential for cost savings is substantial. Preventing heart failure in high-risk patients could generate $250,000–$350,000 in savings per patient annually. On a national scale, the company estimates billions in avoidable healthcare spending could be reduced through early interventions. This has broader implications for health systems, insurers, and patients who stand to benefit from more efficient and preventive care.

Dr. MacLaughlin noted that AI should complement, not replace, clinical expertise. DeLorean AI's platform is designed to empower clinicians with real-time visibility and actionable intelligence, enabling them to intervene earlier and improve outcomes. The company has seven patents in process and is expanding from B2B partnerships to direct-to-patient engagement. This shift aims to make data-driven healthcare accessible to a broader audience.

Future Developments and Expansion

DeLorean AI is also preparing to integrate its platform into more diverse disease areas, including chronic kidney disease, diabetes, COPD, and depression. The company's focus is on transparency, clinical validation, and ethical AI to ensure real-world applicability. Its AI models are built for real hospitals and real patients, avoiding overpromising while delivering measurable outcomes.

As the healthcare industry increasingly adopts AI-driven solutions, DeLorean AI positions itself as a leader in predictive and preventive care. With strong clinical validation and a large dataset, the company is redefining how chronic and acute conditions are managed. By bridging the gap between data science and clinical practice, DeLorean AI is helping to drive a shift toward more proactive, personalized, and cost-effective care.